Relationships between the Microbiome and Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal CancerOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated how the tissue microbiome relates to response to neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer. It tracked microbial changes before and after treatment. The team compared tumor versus normal tissue, pre- versus post-nCRT samples, and responders versus non-responders. Microbes were profiled from tissue DNA using the PathSeq pipeline. Diversity, differential abundance, network analysis, and a Bayesian network prediction model were used to link the microbiome to treatment response.
Who was studied?
The cohort was 26 patients with locally advanced rectal cancer, contributing 103 tissue samples. Nine patients (34.6 percent) were responders and 17 (65.4 percent) were non-responders. Median age was about 60 to 61 years. All received concurrent chemoradiotherapy with capecitabine or 5-fluorouracil, followed by surgery. Both tumor and adjacent normal rectal tissue were sampled at pre-nCRT biopsy and post-nCRT surgery. Samples were formalin-fixed paraffin-embedded specimens from an archival tissue repository.
What were the most important findings?
Tumor and adjacent normal tissue showed nearly identical microbiomes before treatment. After nCRT, diversity fell sharply (observed OTUs p less than 0.001), and Proteobacteria rose while Firmicutes and Bacteroidetes declined. Non-responders underwent more extensive shifts, gaining opportunistic pathogens. Responders kept a more stable community enriched in butyrate-producing bacteria at baseline. Network analysis showed butyrate producers forming strong networks in responders and pathogens clustering in non-responders. A five-microbe Bayesian model predicted response with a mean AUC of 0.82 by cross-validation and 0.84 by bootstrapping, with butyrate producers as the key predictors.
What are the greatest implications of this study?
The findings suggest butyrate-producing bacteria mark and may support a favorable response to chemoradiotherapy in rectal cancer. This raises the prospect of microbiome-based tools to guide treatment and non-operative management decisions. The near-identical tumor and normal tissue profiles imply intratumoral bacteria arise from adjacent normal tissue. Limitations include a small cohort, genus-level resolution only, mixed tumor and normal samples in the model, and use of archival paraffin tissue. External validation is needed before clinical use.